Dual therapy in HIV represents an attractive opportunity for HIV infected people in virologic suppression Dual therapy regimens should achieve and maintain viral suppression and immunologic control while minimizing short and long term AEs, improve adherence and convenience and reduce drug drug interactions and costs To date, there are few clinical data to support a dual regimen with dolutegravir and doravirine 1 The individual efficacy of both doravirine and dolutegravir suggests that concomitant administration of these two molecules as part of an NRTI sparing regimen could be a viable option, although to date there are no studies in the HIV infected population The aim of our study is to investigate whether a dual therapy regimen containing dolutegravir and doravirine is effective and safe

M. Trizzino, C. Gioè, A.A. Medaglia, P. Di Carlo, M. Alfonzo, L. Pipitò, et al. (2022). Efficacy and safety of dolutegravir and doravirine dual therapy in the context of antiretroviral therapy switch: 48 weeks analysis. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY.

Efficacy and safety of dolutegravir and doravirine dual therapy in the context of antiretroviral therapy switch: 48 weeks analysis.

A. A. Medaglia;P. Di Carlo;
2022-10-25

Abstract

Dual therapy in HIV represents an attractive opportunity for HIV infected people in virologic suppression Dual therapy regimens should achieve and maintain viral suppression and immunologic control while minimizing short and long term AEs, improve adherence and convenience and reduce drug drug interactions and costs To date, there are few clinical data to support a dual regimen with dolutegravir and doravirine 1 The individual efficacy of both doravirine and dolutegravir suggests that concomitant administration of these two molecules as part of an NRTI sparing regimen could be a viable option, although to date there are no studies in the HIV infected population The aim of our study is to investigate whether a dual therapy regimen containing dolutegravir and doravirine is effective and safe
25-ott-2022
Settore MED/17 - Malattie Infettive
HIV Glasgow took place between 23 – 26 October 2022.
Glasgow
23 – 26 October
30
M. Trizzino, C. Gioè, A.A. Medaglia, P. Di Carlo, M. Alfonzo, L. Pipitò, et al. (2022). Efficacy and safety of dolutegravir and doravirine dual therapy in the context of antiretroviral therapy switch: 48 weeks analysis. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY.
File in questo prodotto:
File Dimensione Formato  
P101_Trizzino.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 266.91 kB
Formato Adobe PDF
266.91 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/589133
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact